Multiple sclerosis progression: time for a new mechanism-driven framework.
Kuhlmann T, Moccia M, Coetzee T, Cohen JA, Correale J, Graves J, Marrie RA, Montalban X, Yong VW, Thompson AJ, Reich DS; International Advisory Committee on Clinical Trials in Multiple Sclerosis.
Lancet Neurol. 2023 Jan;22(1):78-88. doi: 10.1016/S1474-4422(22)00289-7. Epub 2022 Nov 18.
Primary Progressive Multiple Sclerosis-A Key to Understanding and Managing Disease Progression.
Sempik I, Dziadkowiak E, Moreira H, Zimny A, Pokryszko-Dragan A.
Int J Mol Sci. 2024 Aug 11;25(16):8751. doi: 10.3390/ijms25168751.
Primary Progressive Multiple Sclerosis: New Therapeutic Approaches.
Rajabi M, Shafaeibajestan S, Asadpour S, Alyari G, Taei N, Kohkalani M, Raoufinia R, Afarande H, Saburi E.
Neuropsychopharmacol Rep. 2025 Sep;45(3):e70039. doi: 10.1002/npr2.70039.
Diagnosis and treatment of progressive multiple sclerosis: A position paper.
Pozzilli C, Pugliatti M, Vermersch P, Grigoriadis N, Alkhawajah M, Airas L, Oreja-Guevara C.
Eur J Neurol. 2023 Jan;30(1):9-21. doi: 10.1111/ene.15593. Epub 2022 Oct 25.
Progressive multiple sclerosis: pathology and pathogenesis.
Lassmann H, van Horssen J, Mahad D.
Nat Rev Neurol. 2012 Nov 5;8(11):647-56. doi: 10.1038/nrneurol.2012.168. Epub 2012 Sep 25.
Progressive Multiple Sclerosis.
Amezcua L.
Continuum (Minneap Minn). 2022 Aug 1;28(4):1083-1103. doi: 10.1212/CON.0000000000001157.
Primary-progressive multiple sclerosis.
Miller DH, Leary SM.
Lancet Neurol. 2007 Oct;6(10):903-12. doi: 10.1016/S1474-4422(07)70243-0.
Primary progressive multiple sclerosis.
Montalban X.
Curr Opin Neurol. 2005 Jun;18(3):261-6. doi: 10.1097/01.wco.0000169742.37159.e9.
Progressive Multiple Sclerosis.
Ontaneda D.
Continuum (Minneap Minn). 2019 Jun;25(3):736-752. doi: 10.1212/CON.0000000000000727.
Pathophysiology, Diagnosis, Treatment and Emerging Neurotherapeutic Targets for Progressive Multiple Sclerosis: The Age of PIRA.
Carlson AK, Fox RJ.
Neurol Clin. 2024 Feb;42(1):39-54. doi: 10.1016/j.ncl.2023.07.002. Epub 2023 Aug 21.
